ns 1619 has been researched along with Cardiometabolic Syndrome in 1 studies
NS 1619: structure given in first source
NS 1619 : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which the hydrogens at positions 1 and 5 are replaced are replaced by 2-hydroxy-5-(trifluoromethyl)phenyl and trifluoromethyl groups, respectively. It is an opener/activator of the large-conductance calcium-activated potassium channel (Bkca).
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borbouse, L | 1 |
| Dick, GM | 1 |
| Asano, S | 1 |
| Bender, SB | 1 |
| Dincer, UD | 1 |
| Payne, GA | 1 |
| Neeb, ZP | 1 |
| Bratz, IN | 1 |
| Sturek, M | 1 |
| Tune, JD | 1 |
1 other study available for ns 1619 and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Impaired function of coronary BK(Ca) channels in metabolic syndrome.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 2-Chloroadenosine; 3-Pyridinecar | 2009 |